Plasmapp, a bio-plasma deep-tech company, announced on the 6th that its medical implant surface processor (brand: ACTILINK) product has obtained China CVC certification (Certainty Value-added Credibility).

CVC certification is a certification in China that proves that product quality, safety, environmental protection, and performance meet relevant standards.

Although it is difficult because it involves product safety evaluation and factory inspection, it is a certification that provides a clear guarantee of quality and consumer safety upon obtaining the certificate.

According to the company, the Plasmapp surface treatment that obtained CVC certification is a technology that efficiently generates plasma in a vacuum environment through atmospheric exhaust to remove impurities on the implant surface and improve implant performance by improving surface energy.

The plasma surface treatment technology independently developed by Plasmapp has received New Technology Certification (NET) from the Ministry of Trade, Industry and Energy and the Ministry of Health and Welfare, and has acquired New Product Certification (NEP) from the Ministry of Trade, Industry and Energy.

Plasmapp received verification evaluation and certification for its performance and reliability from the Cleanimplant foundation in Germany to promote rapid global commercialization.

Since then, it has acquired European CE, Japanese VCCI, and Eurasian EAC certification, and has recently received Chinese CVC certification, accelerating its global commercialization.

Plasmapp CEO Youbong Lim said, “We are deriving requirements and promoting commercialization by considering entry into the global market from the product development planning stage, so it is possible to secure global certification quickly.”

“We will quickly expand the implant surface treatment technology, which is rapidly expanding in the global dental market, to the orthopedic market to increase the technological gap and lead the market,” he said.

Source: Pharm News ( https://www.pharmnews.com/news/articleView.html?idxno=219497 )